Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Sunesis Pharmaceuticals Inc - Key Facts

Sunesis Pharmaceuticals Inc - Key Employees

Sunesis Pharmaceuticals Inc - Key Employee Biographies

Sunesis Pharmaceuticals Inc - Major Products and Services

Sunesis Pharmaceuticals Inc - History

Sunesis Pharmaceuticals Inc - Company Statement

Sunesis Pharmaceuticals Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Sunesis Pharmaceuticals Inc - Business Description

Sunesis Pharmaceuticals Inc - Corporate Strategy

Sunesis Pharmaceuticals Inc - SWOT Analysis

SWOT Analysis - Overview

Sunesis Pharmaceuticals Inc - Strengths

Sunesis Pharmaceuticals Inc - Weaknesses

Sunesis Pharmaceuticals Inc - Opportunities

Sunesis Pharmaceuticals Inc - Threats

Sunesis Pharmaceuticals Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Sunesis Pharmaceuticals Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Mar 07, 2019: Sunesis Pharmaceuticals reports fourth quarter and full-year 2018 financial results and recent highlights

Jan 02, 2019: Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies

Nov 05, 2018: Sunesis Pharmaceuticals reports third quarter 2018 financial results and recent highlights

Aug 07, 2018: Sunesis Pharmaceuticals reports second quarter 2018 financial results and recent highlights

Jul 09, 2018: Sunesis Pharmaceuticals Announces Senior Management Changes

May 08, 2018: Sunesis Pharmaceuticals Announces First Quarter 2018 Financial Results

Mar 08, 2018: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights

Feb 07, 2018: Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Sunesis Pharmaceuticals Inc (SNSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company's Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). It is a first-in-class anti-cancer quinolone derivative that has not been used previously for the treatment of cancer. The drug candidate is also being evaluated in Phase III clinical trials for the treatment of myelodysplastic syndromes (MDS). Its other products under pipeline include TAK-580 and SNS-510 for solid tumors, and Vecabrutinib (SNS-062) for B-cell malignancies. The company collaborates with pharmaceutical companies such as Biogen, Millennium Pharmaceuticals, Inc. and Sumitomo Dainippon to obtain licenses to develop certain products. Sunesis is headquartered in South San Francisco, California, the US.

Sunesis Pharmaceuticals Inc Key Recent Developments

Mar 07,2019 Sunesis Pharmaceuticals reports fourth quarter and full-year 2018 financial results and recent highlights
Jan 02,2019 Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies
Nov 05,2018 Sunesis Pharmaceuticals reports third quarter 2018 financial results and recent highlights
Aug 07,2018 Sunesis Pharmaceuticals reports second quarter 2018 financial results and recent highlights

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company